Patient number | Age | ER (%) | PR (%) | HER2 (+/−) | Ki67 (%) | Grade | Tumor size | LN mets | Anti-hormonal therapy |
---|---|---|---|---|---|---|---|---|---|
1 | 62 | 95 | 70 | − | 5 | 1 | pT1b | pN1a | − |
2 | 58 | 95 | 95 | − | 10 | 2 | T1b | N0 | − |
3 | 50 | 100 | 100 | + | 5 | 1 | pT1 | pN0 | Tamoxifen |
4 | 73 | 95 | 2 | − | 25 | 2 | pT2 | pN1a | − |
5 | 49 | 90 | 80 | − | 10 | 2 | T1b | pN0 | Tamoxifen |
6 | 69 | 100 | 100 | − | 15 | 2 | pT1a | pN0 | Tamoxifen |
7 | 53 | 95 | 60 | − | 10 | 2 | pT1c | pN0 | Letrozole |
8 | 73 | 100 | 0 | − | 20 | na | pT1c | pN0 | Tamoxifen |
9 | 67 | 90 | 80 | − | 5 | 1 | pT1b | pN0 | Tamoxifen |
10 | 66 | 100 | 100 | − | 5 | 2 | pT1c | pN0 | Letrozole |
11 | 64 | 95 | 80 | − | 10 | 1 | pT1b | pN0 | Letrozole |
12 | 61 | 80 | 100 | − | 10 | 2 | pT1b | pN0 | Anastrozole |
13 | 43 | 95 | 95 | − | 10 | 2 | pT1c | pN0 | Tamoxifen |